-+ 0.00%
-+ 0.00%
-+ 0.00%

BENITEC BIOPHARMA ANNOUNCES POSITIVE INTERIM PHASE 1B/2A RESULTS FOR HIGH DOSE BB-301 AND CONTINUED DURABLE IMPROVEMENTS FOR LOW DOSE BB-301 TREATMENT AT THE 2026 MUSCULAR DYSTROPHY ASSOCIATION CLINICAL & SCIENTIFIC CONFERENCE

Reuters·03/09/2026 11:00:02

Please log in to view news